Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05926960
Title A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)
Acronym PORTSIDE
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Pfizer
Indications
Therapies
Age Groups: senior | adult
Covered Countries ITA | GBR | ESP | DEU

Additional content available in CKB BOOST